[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Laboratoires Elerte\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":108},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100640315","observational-study-of-siropsedal-in-acute-cough-100640315",false,"NCT07625683","Observational Study of SIROPSEDAL in Acute Cough","Prospective Multicenter Before-After Study in Children and Adults Treated for Acute Cough With SIROPSEDAL","SIROPSEDAL","Inclusion Criteria:\n\n* Age greater than or equal to 1 year.\n* Acute cough evolving for less than 10 days.\n* Cough intensity VAS greater than 40\u002F100.\n* SIROPSEDAL prescribed independently from study participation.\n* No hospitalization required.\n* Written informed consent from the patient or from parent(s)\u002Flegal representative for minors, as applicable.\n* Able to attend the Day 7 +\u002F- 1 day visit or teleconsultation.\n* Affiliated with or beneficiary of a health insurance system.\n\nExclusion Criteria:\n\n* ACE inhibitor or sartan use.\n* Asthma or COPD.\n* Corticosteroids ongoing or within the previous 3 days.\n* Antibiotics ongoing or within the previous 3 days.\n* Antitussives ongoing or within the previous 3 days.\n* Antihistamines ongoing or within the previous 3 days.\n* Aerosol therapy ongoing or within the previous 3 days.\n* Severe signs suggesting a causal disease requiring additional investigations according to the investigator.\n* Severe signs requiring corticosteroids, aerosol therapy or centrally acting antitussive treatment according to the investigator.\n* Any contraindication listed in the instructions for use.\n* Patient under legal protection.\n* Pregnancy.\n* Intolerance, hypersensitivity or allergy to one or more product components.","ALL","1 Year",{"count":20,"type":21},124,"ESTIMATED","OBSERVATIONAL","This prospective, multicenter, observational post-market clinical follow-up study evaluates the performance and safety of SIROPSEDAL in children and adults with acute cough treated in routine clinical practice. Patients prescribed SIROPSEDAL independently of study participation will be followed for 7 +\u002F- 1 days using patient-reported outcomes including a cough visual analog scale and the Cough Symptom Score.",[25,26,27],"Acute Cough","Upper Respiratory Tract Infection","Common Cold",[29,30,31,32,33],"acute cough","cough","cough syrup","PMCF","Cough Symptom Score","NOT_YET_RECRUITING","2026-06-02",{"date":37,"type":38},"2026-06-04","ACTUAL",{"date":40,"type":21},"2026-10-15",{"date":42,"type":21},"2027-09-30",{"name":44,"class":45},"Laboratoires Elerte","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100639225","observational-study-of-orosedal-in-sore-throat-and-minor-oral-lesions-100639225","NCT07620353","Observational Study of OROSEDAL in Sore Throat and Minor Oral Lesions","Relief of Sore Throat Pain or Minor Mouth Lesions, Including Minor Aphthous Ulcers, in Children and Adults Treated With OROSEDAL: An Observational Study","Inclusion Criteria:\n\n* Age 8 years or older, including adults.\n* Sore throat or minor mouth lesion, including minor aphthous ulcer or histologically confirmed oral lichen planus, evolving for less than 15 days.\n* Global pain intensity over the previous 24 hours, spontaneous and\u002For during chewing or swallowing, \\>40 mm on a 0-100 mm visual analog scale.\n* OROSEDAL prescription decided by the investigator before inclusion.\n* Written informed consent from the patient or from one parent for minors.\n\nExclusion Criteria:\n\n* More than 3 visible oral mucosal lesions.\n* Post-intubation sore throat.\n* Corticosteroid use ongoing or within 3 days before inclusion.\n* NSAID use ongoing or within 3 days before inclusion.\n* Local treatment on the lesion ongoing or within 3 days before inclusion.\n* Non-opioid analgesics, including paracetamol, ongoing or within 3 days before inclusion, unless continued for at least 24 hours at the same daily dose as during the 24 hours before inclusion.\n* Weak or strong opioid analgesics ongoing or within 3 days before inclusion.\n* Signs suggesting a condition requiring additional investigations according to the investigator, except rapid streptococcal throat testing.\n* Signs suggesting a condition requiring corticosteroid prescription according to the investigator.\n* Systemic disease, such as rheumatoid arthritis, lupus, or Behçet disease.\n* Any contraindication listed in OROSEDAL instructions for use.\n* Known allergy to any OROSEDAL component, including glycerol, tamarind extract, mallow extract, benzyl alcohol, orange blossom flavoring, or xylitol.\n* Non-compliance with precautions for use listed in the instructions for use.","8 Years",{"count":20,"type":21},"This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study will evaluate the performance and safety of OROSEDAL in children and adults with sore throat or minor oral lesions, including minor aphthous ulcers and histologically confirmed oral lichen planus. OROSEDAL is prescribed in routine practice before inclusion. Patients will be followed for 6 ± 1 days and will complete self-assessments of pain, swallowing discomfort, treatment use, and adverse events.",[58,59,60,61,62],"Sore Throat","Aphthous Ulcer","Oral Lichen Planus","Minor Mouth Lesion","Oral Pain",[64,65,66,67,32,68,69],"sore throat","aphthous ulcer","mouth ulcer","oral lesion","real-world evidence","swallowing discomfort","RECRUITING","2026-05-27",{"date":35,"type":38},{"date":74,"type":38},"2026-03-05",{"date":76,"type":21},"2027-07",{"name":44,"class":45},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":88,"conditions":89,"keywords":94,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":46},"100637983","observational-study-of-rhinosedal-in-acute-nasal-obstruction-100637983","NCT07620522","Observational Study of RHINOSEDAL in Acute Nasal Obstruction","Prospective Multicenter Before-After Study in Children and Adults Treated for Acute Nasal Obstruction With RHINOSEDAL","RHINOSEDAL","Inclusion Criteria:\n\n* Age 8 years or older.\n* Acute nasal obstruction evolving for less than 48 hours associated with common cold, allergic or non-allergic rhinitis, or rhinosinusitis.\n* Baseline NOSE score \\>40\u002F100.\n* No warning signs such as pus, unilateral obstruction, bleeding, or pain.\n* RHINOSEDAL prescribed by the investigator.\n* Written informed consent signed.\n* Affiliated with a health insurance system.\n\nExclusion Criteria:\n\n* Known anatomical cause of chronic nasal congestion.\n* Corticosteroid use within the previous 2 days.\n* NSAID use within the previous 2 days.\n* Sympathomimetic use within the previous 2 days.\n* Nasal decongestant or nasal irrigation within the previous 2 days.\n* Antihistamines unless stable for more than 48 hours and maintained.\n* Contraindication listed in the RHINOSEDAL instructions for use.\n* Patient under legal protection.\n* Pregnant or breastfeeding women.",{"count":87,"type":21},126,"This prospective, multicenter, national, observational, non-interventional post-market clinical follow-up study evaluates the performance and safety of RHINOSEDAL in children and adults presenting with acute nasal obstruction associated with common cold, allergic or non-allergic rhinitis, or rhinosinusitis. Patients prescribed RHINOSEDAL in routine care will be followed for 6 ±1 days using patient-reported outcome measures including the NOSE score.",[90,27,91,92,93],"Nasal Obstruction","Allergic Rhinitis","Non-allergic Rhinitis","Rhinosinusitis",[95,96,97,98,99,100,101,102,32,68],"nasal obstruction","NOSE score","rhinitis","rhinosinusitis","common cold","nasal congestion","saline irrigation","medical device",{"date":35,"type":38},{"date":40,"type":21},{"date":106,"type":21},"2027-12-31",{"name":44,"class":45},""]